Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality


Tags Uveitis
Journal Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

Ophthalmology Volume 130, Number 12, December 2023


本研究旨在確定所有因素(all cause mortality)和癌症死亡率 (cancer mortality, CM) 的發生率。研究採用回顧性的族群研究設計,針對眼部發炎疾病 (ocular inflammatory disease,OID) 的專科中心進行研究。研究人員回顧性地收集了從1979年至2010年期間(共31年)的資料,並通過國家死亡指數進行整體和癌症特異性死亡的確定。研究結果顯示,暴露於肿瘤壞死因子抑製劑tumor necrosis factor inhibitors、抗代謝劑antimetabolites、鈣調蛋白酶抑製劑calcineurin inhibitor和烷化劑alkylating agents的患者與未暴露於任何免疫抑制劑的患者相比,整體死亡率和 CM 正常的預期程度。這些結果表明,免疫抑制劑對於治療各種炎症性疾病的患者的整體死亡率和 CM 是安全的。

English Abstract

The purpose of this retrospective cohort study was to determine the incidence of all-cause and cancer mortality in patients with ocular inflammatory disease (OID) who were treated with immunosuppressive drugs. The study collected data from clinic records from 1979 to 2010 and followed the patients through National Death Index linkage. The study found that overall mortality and cancer mortality were not significantly increased in patients exposed to tumor necrosis factor inhibitors, antimetabolites, calcineurin inhibitors, or alkylating agents compared to patients not exposed to these drugs.